Read more at:
BENGALURU: Biocon Biologics is focusing on innovative business models to reduce the cost of human insulin and cancer drugs, as it looks to build a pipeline of 28 biosimilars across global markets, the company’s chief executive said.
The Biocon subsidiary will chart a path that ensures high volumes and low costs, unlike competitors, Christiane Hamacher, chief executive of Biocon Biologics told ET.
“We want to be the Amazon of biotech pharma going beyond the product. ..